ViraferonPeg (peginterferon-α-2b) / Merck (MSD)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

   Remove FilterRemove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
BEAT-2, NCT03588715: Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074

Active, not recruiting
1
15
US
Pegylated Interferon alpha 2b (peg-IFN-α2b), Pegintron, 3BNC117 + 10-1074, Broadly Neutralizing Antibodies
Luis Montaner, University of Pennsylvania, Philadelphia Fight, Rockefeller University, Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID)
HIV, HIV/AIDS, HIV-1 Infection
12/21
10/22

Download Options